Comprehensive coverage of GLP-1 receptor agonist market dynamics, including Eli Lilly's portfolio (Zepbound, Mounjaro), competitive positioning against Novo Nordisk, clinical efficacy comparisons, pipeline developments, regulatory considerations, and market expansion into obesity, diabetes, and other therapeutic areas.
While compounding restrictions protect margins this year, accelerating international patent expirations pose significant downward pressure on future earnings potential.
While Lilly's pipeline advantages position it for market dominance, supply chain vulnerabilities and illicit competition create significant downside scenarios for investors.
